Group 1: Company Actions - The company held its 11th meeting of the 4th Board of Directors on February 5, 2026, approving a proposal to use idle funds for cash management, planning to utilize up to 1.48 billion yuan, with a maximum of 80 million yuan from idle raised funds and 1.4 billion yuan from self-owned funds, to invest in high-security, liquid financial products to enhance fund efficiency [1] - The proposal will be submitted for review at a temporary shareholders' meeting on February 26, 2026, and if approved, the fund usage period will be 12 months [1] Group 2: Stock Performance - Over the past 7 days (February 5 to 11, 2026), the company's stock price fluctuated by 1.12%, with a high of 34.31 yuan on February 10 and a low of 33.11 yuan on February 6 [2] - The latest closing price on February 11 was 33.53 yuan, down 1.50% for the day, with a trading volume of 42.35 million yuan; on February 10, there was a net outflow of 164,800 yuan in main funds, while the stock price increased by 1.16% [2] - Technical analysis indicates the stock is in a bullish trend, with a 20-day resistance level at 33.93 yuan and a support level at 31.91 yuan [2] Group 3: Institutional Insights - Dongguan Securities included the company as a focus in the scientific services sector in its biweekly report on the pharmaceutical and biotechnology industry published on February 6, 2026, noting that the industry is experiencing an overall pullback due to the impact of the 11th batch of national procurement, but future industries like brain-computer interfaces are receiving policy support [3] - The institution forecasts a 32.08% year-on-year growth in net profit and a 19.79% year-on-year growth in revenue for the company in 2025 [3]
优宁维拟用14.8亿闲置资金理财，股价近期小幅震荡